Evidence map›Paper›PMID 33431617›Full record

ArticleOpen heart2021

Characterisation of the patients with suspected heart failure: experience from the SHEAF registry.

Pankaj Garg, Ahmed Dakshi, Hosamadin Assadi, Andrew J Swift, Umna Naveed, Graham Fent, Nigel Lewis, Dominic Rogers, Athanasios Charalampopoulos, Abdallah Al-Mohammad

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Open heart, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Pankaj GargIICD, The University of Sheffield, Sheffield, UK.ORCID 0000-0002-5483-169X
Ahmed DakshiCardiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Hosamadin AssadiIICD, The University of Sheffield, Sheffield, UK.ORCID 0000-0002-6143-8095
Andrew J SwiftAcademic Unit of Radiology, The University of Sheffield, Sheffield, UK.
Umna NaveedIICD, The University of Sheffield, Sheffield, UK.
Graham FentCardiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Nigel LewisIICD, The University of Sheffield, Sheffield, UK.
Dominic RogersCardiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Athanasios CharalampopoulosCardiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Abdallah Al-MohammadIICD, The University of Sheffield, Sheffield, UK abdallah.al-mohammad@nhs.net.ORCID 0000-0001-6517-8692
Sheffield Teaching Hospitals NHS Foundation Trust · GBUniversity of Sheffield · GB

Funding

Wellcome TrustWellcome Trust AS: 205188/Z/16/Z
6 · The paper itself

Abstract

objectivesTo characterise and risk-stratify patients presenting to a heart failure (HF) clinic according to the National Institute for health and Care Excellence (NICE) algorithm.

methodsThis is an observational study of prospectively collected data in the Sheffield HEArt Failure registry of consecutive patients with suspected HF between April 2012 and January 2020. Outcome was defined as all-cause mortality.

results6144 patients were enrolled: 71% had HF and 29% had no HF. Patients with N-terminal pro-brain-type natriuretic peptide (NT-proBNP) >2000 pg/mL were more likely to have HF than those with NT-proBNP of 400-2000 pg/mL (92% vs 64%, respectively). Frequency of HF phenotypes include: HF with preserved ejection fraction (HFpEF) (33%), HF with reduced ejection fraction (HFrEF) (29%), HF due to valvular heart disease (4%), HF due to pulmonary hypertension (5%) and HF due to right ventricular systolic dysfunction (1%). There were 1485 (24%) deaths over a maximum follow-up of 6 years. The death rate was higher in HF versus no HF (11.49 vs 7.29 per 100 patient-years follow-up, p<0.0001). Patients with HF and an NT-proBNP >2000 pg/mL had lower survival than those with NT-proBNP 400-2000 pg/mL (3.8 years vs 5 years, p<0.0001). Propensity matched survival curves were comparable between HFpEF and HFrEF (p=0.88).

conclusionOur findings support the use by NICE's HF diagnostic algorithm of tiered triage of patients with suspected HF based on their NT-proBNP levels. The two pathways yielded distinctive groups of patients with varied diagnoses and prognosis. HFpEF is the most frequent diagnosis, with its challenges of poor prognosis and paucity of therapeutic options.

Indexed as

RegistriesAgedAged, 80 and overBiomarkersFemaleHeart FailureHospitalizationHumansMaleNatriuretic Peptide, BrainPeptide FragmentsPrognosisProtein PrecursorsStroke VolumeBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Protein Precursorsdiastolicepidemiologyheart failuresystolic

Identifiers

PMID33431617
PMCPMC7802648
OpenAlexW3119512526

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.